Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|December 11, 2009
Sparta Systems Promotes William B. Gerraughty, Jr. to Chief Operating Officer
Advertisement
Sparta Systems, Inc., has promoted William B. Gerraughty, Jr., to the role of chief operating officer (COO). Gerraughty, who currently serves as chief financial officer (CFO), will assume the responsibility of overseeing the company’s day-to-day operations, provide strategic planning and resource allocation, and advise the CEO and management team on key planning issues and important business decisions. Gerraughty will continue to serve as CFO and manage the company’s legal and human resource departments.
Before Sparta Systems, Gerraughty served as CFO at two publicly traded companies, NMS Communications and Infinium Software. He also held a number of executive positions, including president, COO and CFO at Intellution, a software company serving the industrial automation markets. Gerraughty began his career at Coopers and Lybrand.
“William Gerraughty’s success in ensuring the financial health of Sparta Systems makes him a natural choice to oversee the company’s daily operation as we head into 2010,” said James E. McGowan, CEO, Sparta Systems. “I’m confident that with his unparalleled record of accomplishment and complete knowledge of the company’s inner workings, his promotion to COO will help position Sparta for continued growth in the coming year and beyond.”
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5